FDA approves Eli Lilly's Onswik once-weekly insulin for type 2 diabetes

The FDA has approved Eli Lilly's once-weekly basal insulin Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes, offering a treatment that reduces the injection burden by over 300 shots per year. Supported by the QWINT Phase 3 trials of 3,400 patients, Onswik demonstrated non-inferiority to daily insulins. The approval marks Onswik's fourth global clearance and intensifies Lilly's market rivalry with Novo Nordisk, which launched its own weekly insulin, Awiqli, in March 2026.

FDA approval and indications for Onswik

• ▪The U.S. Food and Drug Administration approved Eli Lilly and Company's once-weekly basal insulin Onswik, chemically known as insulin efsitora alfa-gobe, for adults with type 2 diabetes on September 24, 2026.
• ▪Onswik is approved alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes, providing steady basal insulin levels throughout a seven-day period.
• ▪Eli Lilly and Company's Onswik label states that the drug should not be used in patients with type 1 diabetes due to an increased risk of severe hypoglycemia, or dangerously low blood sugar.
• ▪The U.S. Food and Drug Administration decision marks the fourth global approval for Onswik, which has already received regulatory clearance in Europe, Mexico, and Japan.

Clinical trial results for Onswik

• ▪In the QWINT-2 trial, Onswik lowered A1C by 1.34% compared with a 1.26% reduction in patients taking insulin degludec, demonstrating non-inferiority to standard once-daily options.
• ▪The QWINT Phase 3 clinical program, which tested Onswik in more than 3,400 adults across four global registration studies starting in 2022, supported the drug's regulatory approval.
• ▪The QWINT clinical program showed that Onswik achieved similar A1C reductions and a comparable safety profile to daily basal insulins glargine and degludec.

Lilly stock reaction

• ▪Eli Lilly and Company's stock broke above the $1,150 area and approached the $1,200 resistance zone on September 24, 2026.
• ▪Eli Lilly and Company's shares rose 3.56% to $1,191.92 following the announcement of the U.S. Food and Drug Administration's approval of Onswik.

Competition with Novo Nordisk's Awiqli

• ▪The approval of Onswik sets up a market battle between Eli Lilly and Company and Novo Nordisk, which received FDA approval for its once-weekly insulin Awiqli in March 2026.
• ▪Novo Nordisk's Awiqli became the first once-weekly insulin available in the United States after a September 2025 refiling, following two FDA rejections in 2024 over manufacturing and type 1 diabetes concerns.

Debatable claims

• ▪The FDA is justified in withholding once-weekly insulin approvals from type 1 diabetes patients
• ▪Non-inferiority to existing drugs is an adequate standard for approving new diabetes treatments
• ▪Once-weekly insulin is a superior treatment option to daily basal insulin for type 2 diabetes